Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel Free BTAI Stock Alerts

BioXcel Therapeutics (BTAI) Financials

BioXcel Therapeutics logo
$0.82 -0.02 (-2.42%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$0.82 +0.00 (+0.43%)
As of 07/10/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for BioXcel Therapeutics

Annual Income Statements for BioXcel Therapeutics

This table shows BioXcel Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -4.54 -19 -33 -82 -107 -166 -179 -60 -70
Consolidated Net Income / (Loss)		 -4.54 -19 -33 -82 -107 -166 -179 -60 -70
Net Income / (Loss) Continuing Operations		 -4.54 -19 -33 -82 -107 -166 -179 -60 -70
Total Pre-Tax Income 		-4.54 -19 -33 -82 -107 -166 -179 -60 -70
Total Operating Income		 -4.54 -20 -34 -82 -107 -160 -172 -67 -50
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.36 0.12 0.12 0.48
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.38 1.38 2.27 0.64
Operating Revenue		 - - - - 0.00 0.38 1.38 2.27 0.64
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.02 1.26 2.14 0.16
Operating Cost of Revenue		 - - - - 0.00 0.02 1.26 2.14 0.16
Total Operating Expenses		 4.54 20 34 82 107 160 172 67 51
Selling, General & Admin Expense		 1.85 5.40 7.80 24 54 69 83 34 20
Research & Development Expense		 2.69 15 26 58 53 91 84 30 30
Restructuring Charge		 - - - - - 0.00 4.16 2.44 0.19
Total Other Income / (Expense), net		 -0.00 0.69 0.63 0.13 0.00 -6.11 -7.27 7.65 -19
Interest Expense		 - - 0.02 0.03 0.04 8.21 13 15 17
Interest & Investment Income		 -0.00 0.69 0.65 0.16 0.04 2.53 5.65 2.60 1.07
Other Income / (Expense), net		 - - - - 0.00 -0.43 0.39 20 -3.52
Basic Earnings per Share		 ($0.47) ($1.32) ($2.02) ($3.79) ($4.05) ($5.92) ($98.33) ($23.51) ($5.73)
Weighted Average Basic Shares Outstanding		 9.69M 14.57M 16.29M 21.68M 26.37M 28.02M 1.82M 2.54M 12.21M
Diluted Earnings per Share		 ($0.47) ($1.32) ($2.02) ($3.79) ($4.05) ($5.92) ($98.33) ($23.51) ($5.73)
Weighted Average Diluted Shares Outstanding		 9.69M 14.57M 16.29M 21.68M 26.37M 28.02M 1.82M 2.54M 12.21M
Weighted Average Basic & Diluted Shares Outstanding		 9.69M 14.57M 16.29M 21.68M 27.98M 29.01M 30.58M 5.49M 27.07M

Quarterly Income Statements for BioXcel Therapeutics

This table shows BioXcel Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -50 -22 -27 -8.30 -14 -11 -7.25 -19 -31 -13 -13
Consolidated Net Income / (Loss)		 -50 -22 -27 -8.30 -14 -11 -7.25 -19 -31 -13 -13
Net Income / (Loss) Continuing Operations		 -50 -22 -27 -8.30 -14 -11 -7.25 -19 -31 -13 -13
Total Pre-Tax Income 		-50 -22 -27 -8.30 -14 -11 -7.25 -19 -31 -13 -13
Total Operating Income		 -48 -20 -24 -17 -15 -10 -10 -16 -14 -10 -10
Total Gross Profit		 -0.17 -0.34 0.50 1.04 -0.96 -0.47 0.15 0.01 0.09 0.22 -0.08
Total Revenue		 0.34 0.38 0.58 1.10 0.21 0.37 0.17 0.12 0.10 0.26 0.21
Operating Revenue		 0.34 0.38 0.58 1.10 0.21 0.37 0.17 0.12 0.10 0.26 0.21
Total Cost of Revenue		 0.51 0.71 0.08 0.06 1.17 0.83 0.01 0.11 0.01 0.03 0.28
Operating Cost of Revenue		 0.51 0.71 0.08 0.06 1.17 0.83 0.01 0.11 0.01 0.03 0.28
Total Operating Expenses		 48 20 25 18 14 10 10 16 14 11 10
Selling, General & Admin Expense		 24 9.60 13 9.45 7.68 4.10 5.70 5.61 5.38 3.81 7.19
Research & Development Expense		 20 9.93 11 8.03 5.10 5.90 4.55 10 8.74 6.70 2.96
Total Other Income / (Expense), net		 -2.19 -2.38 -2.63 9.00 1.64 -0.37 2.85 -3.34 -17 -2.26 -2.47
Interest Expense		 3.25 3.44 3.61 3.70 3.79 4.03 3.99 4.22 4.37 4.40 4.20
Interest & Investment Income		 1.07 0.95 0.95 0.67 0.62 0.37 0.28 0.23 0.24 0.32 0.21
Other Income / (Expense), net		 -0.01 0.11 0.03 12 4.82 3.30 6.56 0.66 -13 1.81 1.52
Basic Earnings per Share		 ($1.72) ($12.22) ($13.89) ($3.30) ($5.15) ($4.28) ($1.50) ($2.45) ($2.18) ($1.03) ($0.54)
Weighted Average Basic Shares Outstanding		 29.27M 1.82M 1.93M 2.52M 2.65M 2.54M 4.83M 7.84M 14.20M 12.21M 23.57M
Diluted Earnings per Share		 ($1.72) ($12.22) ($13.89) ($3.30) ($5.15) ($4.28) ($1.50) ($2.45) ($2.18) ($1.03) ($0.54)
Weighted Average Diluted Shares Outstanding		 29.27M 1.82M 1.93M 2.52M 2.65M 2.54M 4.83M 7.84M 14.20M 12.21M 23.57M
Weighted Average Basic & Diluted Shares Outstanding		 29.27M 30.58M 37.53M 40.74M 42.75M 5.49M 6.06M 14.56M 21.87M 27.07M 30.88M

Annual Cash Flow Statements for BioXcel Therapeutics

This table details how cash moves in and out of BioXcel Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.89 42 -10 181 20 -39 -129 -35 -1.10
Net Cash From Operating Activities		 -2.20 -14 -27 -66 -82 -135 -155 -72 -58
Net Cash From Continuing Operating Activities		 -2.20 -14 -27 -66 -82 -135 -155 -72 -58
Net Income / (Loss) Continuing Operations		 -4.54 -19 -33 -82 -107 -166 -179 -60 -70
Consolidated Net Income / (Loss)		 -4.54 -19 -33 -82 -107 -166 -179 -60 -70
Depreciation Expense		 0.00 0.02 0.16 0.19 0.30 0.33 0.32 0.31 0.30
Amortization Expense		 - - - - 0.00 0.86 1.37 0.47 1.65
Non-Cash Adjustments To Reconcile Net Income		 1.61 3.08 3.14 15 20 19 20 -7.18 12
Changes in Operating Assets and Liabilities, net		 0.74 2.66 2.57 1.18 4.95 11 2.02 -6.03 -1.33
Net Cash From Investing Activities		 0.00 -0.34 -0.87 -0.32 -0.45 -0.14 -0.02 0.00 0.00
Net Cash From Continuing Investing Activities		 0.00 -0.34 -0.87 -0.32 -0.45 -0.14 -0.02 0.00 0.00
Purchase of Property, Plant & Equipment		 - -0.34 -0.87 -0.32 -0.45 -0.14 -0.02 0.00 0.00
Net Cash From Financing Activities		 3.08 56 18 247 102 96 27 37 57
Net Cash From Continuing Financing Activities		 3.08 56 18 247 102 96 27 37 57
Repayment of Debt		 - -0.37 - - 0.00 -2.65 -0.18 -2.50 0.00
Repurchase of Common Equity		 - - 0.00 -9.02 - 0.00 -0.81 -0.47 -1.61
Issuance of Common Equity		 2.06 57 18 256 101 0.00 - 40 58
Other Financing Activities, net		 0.65 -0.62 0.02 0.60 1.45 0.28 28 -0.05 -0.02
Cash Interest Paid		 - 0.00 0.06 0.03 0.04 2.70 7.55 7.97 9.69

Quarterly Cash Flow Statements for BioXcel Therapeutics

This table details how cash moves in and out of BioXcel Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -38 -25 8.92 -18 -16 -11 1.16 -12 19 -8.56 -12
Net Cash From Operating Activities		 -38 -27 -18 -23 -16 -15 -12 -13 -19 -14 -12
Net Cash From Continuing Operating Activities		 -38 -27 -18 -23 -16 -15 -12 -13 -19 -14 -12
Net Income / (Loss) Continuing Operations		 -50 -22 -27 -8.30 -14 -11 -7.25 -19 -31 -13 -13
Consolidated Net Income / (Loss)		 -50 -22 -27 -8.30 -14 -11 -7.25 -19 -31 -13 -13
Depreciation Expense		 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.07 0.06
Amortization Expense		 0.38 0.31 0.04 0.10 0.11 0.22 0.35 0.39 0.44 0.47 0.50
Non-Cash Adjustments To Reconcile Net Income		 4.66 4.21 4.69 -9.80 -1.38 -1.04 -3.72 3.74 13 -1.65 -1.09
Changes in Operating Assets and Liabilities, net		 7.79 -9.20 4.27 -5.25 -1.49 -3.21 -1.49 2.41 -1.60 -0.55 1.42
Net Cash From Investing Activities		 - - 0.00 - - - 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 - - 0.00 - - - 0.00 - - - 0.00
Purchase of Property, Plant & Equipment		 - - - - - - 0.00 - - - 0.00
Net Cash From Financing Activities		 - 2.12 27 5.30 0.45 4.28 13 0.14 38 5.65 0.23
Net Cash From Continuing Financing Activities		 - 2.12 27 5.30 0.45 4.28 13 0.14 38 5.65 0.23
Repayment of Debt		 - - 0.00 - - - 0.00 - - - -8.11
Repurchase of Common Equity		 - -0.07 -0.12 -0.16 -0.01 -0.18 -0.80 -0.00 -0.69 -0.12 -0.16
Issuance of Common Equity		 - - - - 0.47 - 14 - 38 5.76 8.50
Other Financing Activities, net		 - 2.38 27 -27 - 6.96 -0.00 -14 -0.02 - 0.00
Cash Interest Paid		 - - - - - - 0.00 - - - 3.65

Annual Balance Sheets for BioXcel Therapeutics

This table presents BioXcel Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 1.36 44 36 220 239 206 74 38 45
Total Current Assets		 0.89 43 34 217 237 203 72 37 45
Cash & Equivalents		 0.89 43 32 213 233 194 65 30 28
Restricted Cash		 - - - - - - - 0.00 0.34
Accounts Receivable		 - 0.12 - - 0.00 0.25 0.07 0.13 0.23
Inventories, net		 - - - - 0.00 1.99 1.99 0.68 0.72
Prepaid Expenses		 0.00 0.49 1.68 2.96 2.89 3.07 2.78 5.29 4.03
Other Current Assets		 - - - 0.98 0.96 3.84 2.08 1.44 11
Plant, Property, & Equipment, net		 0.00 0.33 1.04 1.27 1.29 1.08 0.78 0.48 0.18
Total Noncurrent Assets		 0.46 0.05 1.24 1.60 1.33 1.90 0.78 0.47 0.06
Other Noncurrent Operating Assets		 0.46 0.05 1.24 1.60 1.33 1.90 0.78 0.47 0.06
Total Liabilities & Shareholders' Equity		 1.36 44 36 220 239 206 74 38 45
Total Liabilities		 2.34 4.66 9.50 13 18 129 130 131 140
Total Current Liabilities		 2.34 4.66 8.47 12 17 33 27 22 54
Short-Term Debt		 0.37 - - - - - - 0.00 25
Accounts Payable		 0.44 1.60 4.95 4.14 4.88 10 14 16 15
Accrued Expenses		 1.02 3.06 3.12 7.47 11 19 12 5.76 4.34
Other Current Liabilities		 0.51 - 0.40 0.24 0.29 0.83 0.45 0.48 9.95
Total Noncurrent Liabilities		 0.00 0.00 1.03 1.40 1.11 96 103 109 86
Long-Term Debt		 - - - - 0.00 93 101 103 85
Other Noncurrent Operating Liabilities		 - - 1.03 1.40 1.11 3.13 2.35 6.70 1.79
Commitments & Contingencies		 - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -0.98 39 27 207 222 77 -57 -93 -95
Total Preferred & Common Equity		 -0.98 39 27 207 222 77 -57 -93 -95
Preferred Stock		 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -0.98 39 27 207 222 77 -57 -93 -95
Common Stock		 3.47 63 84 346 467 488 534 557 625
Retained Earnings		 -4.45 -24 -57 -139 -246 -412 -591 -650 -720

Quarterly Balance Sheets for BioXcel Therapeutics

This table presents BioXcel Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 100 82 65 49 39 26 45 34
Total Current Assets		 99 81 64 48 38 25 44 34
Cash & Equivalents		 90 74 56 40 31 17 36 17
Restricted Cash		 - - - - - 1.14 1.14 0.00
Accounts Receivable		 0.74 0.38 0.81 0.00 0.00 0.02 0.00 0.22
Inventories, net		 2.02 2.44 2.68 1.53 0.64 0.51 0.46 0.50
Prepaid Expenses		 3.85 2.10 2.78 4.48 4.74 5.15 5.69 3.95
Other Current Assets		 2.17 1.86 1.64 1.40 1.39 1.00 0.93 12
Plant, Property, & Equipment, net		 0.86 0.71 0.63 0.55 0.40 0.32 0.25 0.12
Total Noncurrent Assets		 0.85 0.70 0.63 0.55 0.39 0.22 0.14 0.00
Other Noncurrent Operating Assets		 0.85 0.70 0.63 0.55 0.39 0.22 0.14 0.00
Total Liabilities & Shareholders' Equity		 100 82 65 49 39 26 45 34
Total Liabilities		 141 155 140 135 129 133 134 140
Total Current Liabilities		 39 31 27 26 26 33 38 55
Short-Term Debt		 - - - - 5.61 11 17 22
Accounts Payable		 11 17 13 15 15 17 16 16
Accrued Expenses		 27 14 13 10 3.99 5.09 4.36 6.39
Other Current Liabilities		 0.83 0.47 0.47 0.48 0.50 0.38 0.34 9.93
Total Noncurrent Liabilities		 102 123 112 109 103 100 96 85
Long-Term Debt		 99 102 103 104 100 97 92 78
Other Noncurrent Operating Liabilities		 2.56 22 9.44 4.53 3.27 2.61 3.61 6.72
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -41 -72 -74 -86 -90 -108 -89 -106
Total Preferred & Common Equity		 -41 -72 -74 -86 -90 -108 -89 -106
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -41 -72 -74 -86 -90 -108 -89 -106
Common Stock		 528 545 551 554 567 569 619 627
Retained Earnings		 -568 -617 -626 -639 -657 -677 -708 -733

Annual Metrics And Ratios for BioXcel Therapeutics

This table displays calculated financial ratios and metrics derived from BioXcel Therapeutics' official financial filings.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 15,645,545.00 18,035,025.00 24,368,357.00 27,980,345.00 28,023,225.00 29,272,671.00 - 21,869,491.00
DEI Adjusted Shares Outstanding		 0.00 977,847.00 1,127,189.00 1,523,022.00 1,748,772.00 1,751,452.00 1,829,542.00 - 21,869,491.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -19.71 -29.25 -53.95 -61.15 -94.64 -97.87 - -3.20
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 268.00% 64.20% -71.67%
EBITDA Growth		 0.00% -339.70% -67.69% -145.50% -29.87% -48.99% -6.80% 72.72% -12.38%
EBIT Growth		 0.00% -339.98% -68.32% -144.92% -29.94% -49.69% -7.07% 72.53% -14.67%
NOPAT Growth		 0.00% -339.98% -68.32% -144.92% -29.94% -49.29% -7.60% 60.85% 24.96%
Net Income Growth		 0.00% -324.54% -71.08% -149.24% -30.14% -55.01% -8.02% 66.71% -17.28%
EPS Growth		 0.00% -180.85% -53.03% -87.62% -6.86% -46.17% -8.02% 66.71% 75.63%
Operating Cash Flow Growth		 0.00% -515.16% -100.61% -144.82% -23.82% -64.74% -14.53% 53.53% 20.01%
Free Cash Flow Firm Growth		 0.00% 0.00% -83.68% -161.78% -23.38% -46.23% -17.83% 61.00% 12.50%
Invested Capital Growth		 0.00% -145.39% -50.46% -16.13% -75.95% -83.38% 1.59% -0.26% 28.47%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 173.72% 11.11% -0.44% -14.63%
EBITDA Q/Q Growth		 0.00% 0.00% -3.63% -18.09% -4.92% -20.34% 16.52% 21.24% -2.02%
EBIT Q/Q Growth		 0.00% 0.00% -3.38% -18.22% -4.94% -20.46% 16.40% 21.08% -2.42%
NOPAT Q/Q Growth		 0.00% 0.00% -3.38% -18.22% -4.94% -20.13% 16.12% 12.24% 0.42%
Net Income Q/Q Growth		 0.00% 0.00% -3.78% -18.47% -4.95% -20.93% 15.38% 16.05% -2.47%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -12.46% -0.75% -21.81% 15.38% 16.05% -19.38%
Operating Cash Flow Q/Q Growth		 0.00% -31.59% -15.21% -22.88% 0.41% -16.04% 7.06% 14.34% 1.03%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -34.81% 8.49% -14.15% 2.12% 25.33% -3.02%
Invested Capital Q/Q Growth		 0.00% 0.00% 5.16% 48.57% -53.63% -93.01% 34.02% 5.25% 14.54%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 94.67% 8.70% 5.43% 74.45%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -42,369.33% -12,296.88% -2,043.07% -8,103.89%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -42,572.00% -12,447.97% -2,967.56% -7,859.97%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -42,685.87% -12,419.42% -2,077.32% -8,407.94%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -44,201.87% -12,974.86% -2,630.14% -10,887.38%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.04% 96.53% 98.12% 99.84% 100.00% 103.55% 104.47% 126.61% 129.49%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 462.22% -101.67% -100.23% -70.35% -49.93% -111.08% -1,766.94% 79.67% 74.14%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -71.90% -122.61% -84.03% -129.67%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -74.45% -128.10% -106.39% -167.91%
Return on Common Equity (ROCE)		 462.22% -101.67% -100.23% -70.35% -49.93% -111.08% -1,766.94% 79.67% 74.14%
Return on Equity Simple (ROE_SIMPLE)		 462.22% -49.55% -122.58% -39.75% -48.24% -215.90% 316.86% 64.02% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.18 -14 -24 -58 -75 -112 -120 -47 -35
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -29,800.40% -8,713.58% -2,077.29% -5,501.98%
Net Nonoperating Expense Percent (NNEP)		 -264.17% -24.59% -25.20% -20.01% -14.38% -32.68% -191.59% 23.04% 45.05%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -272.73% -500.39% -249.97%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 5.33% 91.30% 94.57% 25.55%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 18,336.27% 6,044.42% 1,522.15% 3,192.21%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 24,330.40% 6,110.58% 1,343.12% 4,711.99%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 42,666.67% 12,456.67% 2,972.99% 7,934.42%
Earnings before Interest and Taxes (EBIT)		 -4.54 -20 -34 -82 -107 -160 -171 -47 -54
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.54 -20 -33 -82 -107 -159 -170 -46 -52
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 0.00 1.55 9.80 5.45 2.57 7.84 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 1.55 9.80 5.45 2.57 7.84 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 1,605.17 62.58 7.05 54.50
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 1,336.71 88.21 39.12 180.42
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 -0.38 0.00 0.00 0.00 0.00 1.21 -1.78 -1.10 -1.15
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 1.21 -1.78 -1.10 -0.89
Financial Leverage		 0.53 -1.14 -1.14 -1.05 -1.04 -1.11 -3.03 -0.73 -0.81
Leverage Ratio		 -1.38 1.18 1.22 1.10 1.07 1.49 13.79 -0.75 -0.44
Compound Leverage Factor		 -1.38 1.14 1.19 1.10 1.07 1.55 14.41 -0.95 -0.57
Debt to Total Capital		 -60.72% 0.00% 0.00% 0.00% 0.00% 54.79% 228.17% 1,089.70% 775.56%
Short-Term Debt to Total Capital		 -60.72% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 176.43%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 54.79% 228.17% 1,089.70% 599.13%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 160.72% 100.00% 100.00% 100.00% 100.00% 45.21% -128.17% -989.70% -675.56%
Debt to EBITDA		 -0.08 0.00 0.00 0.00 0.00 -0.59 -0.59 -2.21 -2.11
Net Debt to EBITDA		 0.11 0.00 0.00 0.00 0.00 0.63 -0.21 -1.57 -1.55
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.59 -0.59 -2.21 -1.63
Debt to NOPAT		 -0.12 0.00 0.00 0.00 0.00 -0.83 -0.84 -2.18 -3.10
Net Debt to NOPAT		 0.16 0.00 0.00 0.00 0.00 0.90 -0.29 -1.54 -2.29
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.83 -0.84 -2.18 -2.40
Altman Z-Score		 -1.52 6.56 12.26 50.02 17.40 -1.57 -17.75 -27.19 -26.49
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 0.38 9.26 4.03 18.33 14.21 6.17 2.65 1.68 0.83
Quick Ratio		 0.38 9.16 3.83 18.00 13.98 5.90 2.39 1.35 0.53
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -12 -22 -57 -70 -102 -121 -47 -41
Operating Cash Flow to CapEx		 0.00% -3,973.24% -3,115.06% -20,996.84% -18,461.35% -97,367.63% -775,030.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -1,083.29 -2,100.59 -1,749.41 -12.46 -9.06 -3.11 -2.42
Operating Cash Flow to Interest Expense		 0.00 0.00 -1,355.05 -2,457.41 -2,053.83 -16.48 -11.64 -4.76 -3.39
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -1,398.55 -2,469.11 -2,064.95 -16.50 -11.64 -4.76 -3.39
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.04 0.02
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 8.65 22.44 3.53
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.63 1.61 0.23
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.32 1.48 3.60 1.98
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.11 0.14 0.01
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 42.19 16.27 103.47
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 575.89 227.38 1,559.04
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 137,878.75 3,459.10 2,524.51 34,153.09
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 -137,878.75 -2,841.02 -2,280.86 -32,490.58
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 -1.50 -3.68 -5.53 -6.42 -11 -21 -20 -20 -15
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 -0.02 -0.07 -0.11 -0.04
Increase / (Decrease) in Invested Capital		 0.00 -2.18 -1.86 -0.89 -4.88 -9.42 0.33 -0.05 5.82
Enterprise Value (EV)		 59 18 231 913 336 501 122 89 116
Market Capitalization		 60 60 263 1,126 569 602 86 16 35
Book Value per Share		 ($0.10) $2.49 $1.49 $8.48 $7.92 $2.74 ($1.93) ($2.18) ($4.37)
Tangible Book Value per Share		 ($0.10) $2.49 $1.49 $8.48 $7.92 $2.74 ($1.93) ($2.18) ($4.37)
Total Capital		 -0.61 39 27 207 222 170 44 9.41 14
Total Debt		 0.37 0.00 0.00 0.00 0.00 93 101 103 110
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 93 101 103 85
Net Debt		 -0.52 -43 -32 -213 -233 -101 35 73 81
Capital Expenditures (CapEx)		 0.00 0.34 0.87 0.32 0.45 0.14 0.02 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.96 -4.05 -6.79 -7.90 -13 -24 -20 -15 -13
Debt-free Net Working Capital (DFNWC)		 -1.08 39 26 205 220 170 45 15 16
Net Working Capital (NWC)		 -1.45 39 26 205 220 170 45 15 -9.24
Net Nonoperating Expense (NNE)		 1.36 5.30 9.45 25 32 54 59 13 35
Net Nonoperating Obligations (NNO)		 -0.52 -43 -32 -213 -233 -97 36 73 81
Total Depreciation and Amortization (D&A)		 0.00 0.02 0.16 0.19 0.30 1.19 1.69 0.78 1.95
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% -6,334.67% -1,474.28% -648.41% -2,035.36%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 45,325.33% 3,251.88% 669.06% 2,443.93%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 45,325.33% 3,251.88% 669.06% -1,439.41%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.47) ($1.32) ($2.02) ($3.79) ($4.05) ($5.92) ($98.40) ($23.51) ($5.73)
Adjusted Weighted Average Basic Shares Outstanding		 9.69M 15.66M 20.18M 24.57M 26.37M 28.02M 1.82M 2.54M 12.21M
Adjusted Diluted Earnings per Share		 ($0.47) ($1.32) ($2.02) ($3.79) ($4.05) ($5.92) ($98.40) ($23.51) ($5.73)
Adjusted Weighted Average Diluted Shares Outstanding		 9.69M 15.66M 20.18M 24.57M 26.37M 28.02M 1.82M 2.54M 12.21M
Adjusted Basic & Diluted Earnings per Share		 ($0.47) ($1.32) ($2.02) ($3.79) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 9.69M 14.57M 16.29M 21.68M 27.98M 29.01M 1.91M 5.49M 27.07M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.18 -14 -24 -58 -75 -112 -117 -45 -35
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -29,800.40% -8,502.41% -2,001.89% -5,480.83%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -44,201.87% -12,974.86% -2,630.14% -10,887.38%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -1,680.05 -3,048.04 -2,673.38 -19.49 -12.87 -3.11 -3.18
NOPAT to Interest Expense		 0.00 0.00 -1,176.04 -2,133.63 -1,871.36 -13.61 -9.03 -3.11 -2.08
EBIT Less CapEx to Interest Expense		 0.00 0.00 -1,723.55 -3,059.74 -2,684.50 -19.51 -12.87 -3.11 -3.18
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -1,219.54 -2,145.33 -1,882.49 -13.62 -9.03 -3.11 -2.08
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -10.98% 0.00% 0.00% -0.45% -0.80% -2.30%

Quarterly Metrics And Ratios for BioXcel Therapeutics

This table displays calculated financial ratios and metrics derived from BioXcel Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 29,267,197.00 29,272,671.00 30,576,671.00 37,530,821.00 40,743,762.00 - 5,486,038.00 6,056,046.00 14,556,743.00 21,869,491.00 27,074,586.00
DEI Adjusted Shares Outstanding		 1,829,200.00 1,829,542.00 1,911,042.00 2,345,676.00 2,546,485.00 - 5,486,038.00 6,056,046.00 14,556,743.00 21,869,491.00 27,074,586.00
DEI Earnings Per Adjusted Shares Outstanding		 -27.60 -12.16 -14.02 -3.54 -5.36 - -1.32 -3.17 -2.12 -0.57 -0.47
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 148.91% 57.98% 182.52% 141.58% -37.24% -2.66% -71.13% -89.13% -54.21% -30.05% 22.62%
EBITDA Growth		 -23.87% 63.42% 52.89% 90.10% 78.49% 64.42% 87.03% -188.93% -155.12% -14.95% -161.53%
EBIT Growth		 -24.08% 62.97% 53.09% 89.84% 78.31% 63.60% 85.33% -188.33% -155.57% -17.72% -145.88%
NOPAT Growth		 -23.87% 62.42% 52.80% 67.00% 68.34% 47.20% 58.20% 8.35% 6.96% 2.01% -1.23%
Net Income Growth		 -20.77% 59.39% 49.26% 84.49% 72.96% 51.21% 72.92% -131.20% -126.45% -15.53% -74.95%
EPS Growth		 -15.44% 59.39% 49.26% 84.49% 72.96% 51.21% 89.20% 25.76% 57.67% 75.93% 64.00%
Operating Cash Flow Growth		 -20.52% 30.48% 66.18% 39.34% 56.53% 44.87% 31.98% 45.74% -14.99% 4.04% 1.94%
Free Cash Flow Firm Growth		 42.97% 48.40% 148.32% 72.49% -46.92% 48.78% -368.40% -231.17% 27.99% -78.50% 98.95%
Invested Capital Growth		 -187.87% 1.59% -211.53% -26.50% 30.18% -0.26% 65.01% 36.13% 20.70% 28.47% -43.27%
Revenue Q/Q Growth		 -25.38% 10.26% 54.79% 89.69% -80.62% 71.03% -54.10% -28.57% -18.33% 161.22% -19.53%
EBITDA Q/Q Growth		 7.11% 59.50% -23.89% 78.77% -101.94% 33.00% 54.84% -372.93% -78.31% 69.81% -2.74%
EBIT Q/Q Growth		 6.89% 59.08% -22.09% 78.16% -98.79% 31.32% 50.80% -329.24% -76.20% 68.36% -2.76%
NOPAT Q/Q Growth		 7.85% 58.85% -21.59% 28.42% 11.58% 31.39% 3.75% -56.97% 10.24% 27.73% 0.57%
Net Income Q/Q Growth		 5.66% 55.92% -20.38% 69.02% -64.48% 20.45% 33.20% -164.50% -61.10% 59.42% -1.16%
EPS Q/Q Growth		 6.01% 55.92% -20.38% 69.02% -64.48% 20.45% 64.95% -63.33% 11.02% 52.75% 47.57%
Operating Cash Flow Q/Q Growth		 1.63% 28.53% 34.09% -30.88% 29.50% 9.36% 18.68% -4.42% -49.40% 24.36% 16.90%
Free Cash Flow Firm Q/Q Growth		 40.91% -4.43% 194.62% -147.12% -215.54% 63.60% -395.87% 41.86% 31.39% 9.75% 97.07%
Invested Capital Q/Q Growth		 -42.25% 34.02% -119.44% 38.58% 21.49% 5.25% 23.42% -12.12% 2.52% 14.54% -53.38%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 -50.15% -89.63% 86.25% 94.38% -446.73% -127.05% 91.67% 10.83% 88.78% 87.50% -37.38%
EBITDA Margin		 -14,031.09% -5,154.26% -4,125.43% -461.68% -4,809.81% -1,884.15% -1,853.57% -12,272.50% -26,794.90% -3,096.48% -3,953.40%
Operating Margin		 -14,163.34% -5,285.37% -4,151.72% -1,566.67% -7,146.26% -2,866.94% -6,011.31% -13,210.00% -14,518.37% -4,016.41% -4,962.62%
EBIT Margin		 -14,164.81% -5,256.65% -4,146.22% -477.36% -4,895.33% -1,965.85% -2,107.14% -12,662.50% -27,320.41% -3,308.59% -4,225.24%
Profit (Net Income) Margin		 -14,805.28% -5,919.15% -4,603.26% -751.72% -6,378.50% -2,966.94% -4,317.86% -15,989.17% -31,541.84% -4,900.39% -6,160.68%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 104.52% 112.60% 111.02% 157.48% 130.30% 150.92% 204.92% 126.27% 115.45% 148.11% 145.81%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -489.96% -1,766.94% 1,581.24% 315.13% 112.48% 79.67% 49.30% 56.00% 78.16% 74.14% 76.98%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -101.91% -51.90% -55.49% -11.16% -149.21% -79.52% -64.56% -240.97% -438.60% -51.03% -79.16%
Return on Assets (ROA)		 -106.52% -58.44% -61.60% -17.58% -194.42% -120.01% -132.30% -304.28% -506.37% -75.58% -115.42%
Return on Common Equity (ROCE)		 -489.96% -1,766.94% 1,581.24% 315.13% 112.48% 79.67% 49.30% 56.00% 78.16% 74.14% 76.98%
Return on Equity Simple (ROE_SIMPLE)		 521.10% 0.00% 211.50% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -34 -14 -17 -12 -11 -7.35 -7.07 -11 -9.96 -7.20 -7.16
NOPAT Margin		 -9,914.34% -3,699.76% -2,906.20% -1,096.67% -5,002.38% -2,006.86% -4,207.92% -9,247.00% -10,162.86% -2,811.48% -3,473.84%
Net Nonoperating Expense Percent (NNEP)		 -26.05% -27.19% -49.68% -39.63% 7.99% 6.46% 0.36% 11.82% 30.84% 6.97% 7.02%
Return On Investment Capital (ROIC_SIMPLE)		 - -31.55% -57.79% -42.18% -56.92% -78.08% -46.04% -1,090.02% -49.29% -50.93% 136.20%
Cost of Revenue to Revenue		 150.15% 189.63% 13.75% 5.62% 546.73% 227.05% 8.33% 89.17% 11.22% 12.50% 137.38%
SG&A Expenses to Revenue		 7,139.00% 2,553.72% 2,279.04% 855.98% 3,590.19% 1,118.85% 3,392.26% 4,674.17% 5,490.82% 1,486.33% 3,490.78%
R&D to Revenue		 5,753.37% 2,642.02% 1,958.93% 727.54% 2,383.64% 1,612.30% 2,710.71% 8,546.67% 8,918.37% 2,617.58% 1,434.47%
Operating Expenses to Revenue		 14,113.20% 5,195.74% 4,237.97% 1,661.05% 6,699.53% 2,739.89% 6,102.98% 13,220.83% 14,607.14% 4,103.91% 4,925.24%
Earnings before Interest and Taxes (EBIT)		 -48 -20 -24 -5.27 -10 -7.20 -3.54 -15 -27 -8.47 -8.70
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -48 -19 -24 -5.10 -10 -6.90 -3.11 -15 -26 -7.93 -8.14
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 59.62 62.58 49.10 19.99 10.92 7.05 6.01 12.63 49.55 54.50 53.35
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 66.97 88.21 64.76 39.44 39.06 39.12 46.25 116.44 145.04 180.42 175.57
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -2.44 -1.78 -1.40 -1.39 -1.22 -1.10 -1.17 -1.01 -1.23 -1.15 -0.95
Long-Term Debt to Equity		 -2.44 -1.78 -1.40 -1.39 -1.22 -1.10 -1.11 -0.91 -1.04 -0.89 -0.74
Financial Leverage		 -1.48 -3.03 2.05 -0.28 -0.58 -0.73 -0.63 -0.75 -0.78 -0.81 -0.81
Leverage Ratio		 4.00 13.79 -13.56 -3.00 -1.18 -0.75 -0.74 -0.50 -0.54 -0.44 -0.37
Compound Leverage Factor		 4.18 15.53 -15.05 -4.73 -1.54 -1.13 -1.52 -0.63 -0.62 -0.65 -0.54
Debt to Total Capital		 169.43% 228.17% 347.23% 358.84% 555.33% 1,089.70% 687.29% 10,676.33% 540.06% 775.56% -1,908.81%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 36.52% 1,101.77% 83.26% 176.43% -426.93%
Long-Term Debt to Total Capital		 169.43% 228.17% 347.23% 358.84% 555.33% 1,089.70% 650.76% 9,574.56% 456.80% 599.13% -1,481.88%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -69.43% -128.17% -247.23% -258.84% -455.33% -989.70% -587.29% -10,576.33% -440.06% -675.56% 2,008.81%
Debt to EBITDA		 -0.49 -0.59 -0.71 -1.07 -1.78 -2.21 -4.15 -3.10 -2.14 -2.11 -1.76
Net Debt to EBITDA		 -0.04 -0.21 -0.19 -0.49 -1.09 -1.57 -2.93 -2.57 -1.41 -1.55 -1.46
Long-Term Debt to EBITDA		 -0.49 -0.59 -0.71 -1.07 -1.78 -2.21 -3.93 -2.78 -1.81 -1.63 -1.36
Debt to NOPAT		 -0.69 -0.84 -1.00 -1.34 -1.95 -2.18 -2.83 -3.00 -3.08 -3.10 -2.83
Net Debt to NOPAT		 -0.06 -0.29 -0.27 -0.61 -1.19 -1.54 -2.00 -2.49 -2.02 -2.29 -2.35
Long-Term Debt to NOPAT		 -0.69 -0.84 -1.00 -1.34 -1.95 -2.18 -2.68 -2.69 -2.60 -2.40 -2.20
Altman Z-Score		 -8.47 -10.96 -10.39 -12.73 -18.31 -23.76 -23.69 -38.97 -23.73 -23.15 -31.56
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.51 2.65 2.57 2.35 1.87 1.68 1.48 0.76 1.17 0.83 0.62
Quick Ratio		 2.30 2.39 2.37 2.09 1.58 1.35 1.21 0.52 0.96 0.53 0.32
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -14 -14 13 -6.35 -20 -7.29 -36 -21 -14 -13 -0.38
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -4.19 -4.14 3.74 -1.72 -5.29 -1.81 -9.06 -4.98 -3.30 -2.96 -0.09
Operating Cash Flow to Interest Expense		 -11.56 -7.82 -4.91 -6.26 -4.31 -3.67 -3.02 -2.98 -4.30 -3.23 -2.81
Operating Cash Flow Less CapEx to Interest Expense		 -11.56 -7.82 -4.91 -6.26 -4.31 -3.67 -3.02 -2.98 -4.30 -3.23 -2.81
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.01 0.01 0.02 0.03 0.04 0.03 0.02 0.02 0.02 0.02
Accounts Receivable Turnover		 0.00 8.65 5.31 3.87 6.17 22.44 0.00 2.09 0.00 3.53 0.00
Inventory Turnover		 0.32 0.63 0.61 0.59 1.14 1.61 1.35 1.33 0.97 0.23 0.76
Fixed Asset Turnover		 1.21 1.48 2.05 3.06 3.22 3.60 3.35 1.82 1.88 1.98 2.64
Accounts Payable Turnover		 0.06 0.11 0.11 0.11 0.15 0.14 0.13 0.14 0.06 0.01 0.03
Days Sales Outstanding (DSO)		 0.00 42.19 68.70 94.40 59.18 16.27 0.00 174.30 0.00 103.47 0.00
Days Inventory Outstanding (DIO)		 1,124.54 575.89 602.07 614.79 319.31 227.38 270.72 274.01 375.99 1,559.04 481.33
Days Payable Outstanding (DPO)		 5,757.28 3,459.10 3,474.77 3,379.39 2,369.17 2,524.51 2,870.62 2,575.64 5,906.14 34,153.09 13,359.59
Cash Conversion Cycle (CCC)		 -4,632.74 -2,841.02 -2,804.00 -2,670.20 -1,990.68 -2,280.86 -2,599.90 -2,127.33 -5,530.15 -32,490.58 -12,878.26
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -31 -20 -45 -27 -22 -20 -16 -18 -17 -15 -22
Invested Capital Turnover		 -0.06 -0.07 -0.06 -0.10 -0.09 -0.11 -0.06 -0.04 -0.04 -0.04 -0.04
Increase / (Decrease) in Invested Capital		 -20 0.33 -30 -5.76 9.33 -0.05 29 9.93 4.47 5.82 -6.78
Enterprise Value (EV)		 83 122 114 95 89 89 86 101 109 116 119
Market Capitalization		 74 86 86 48 25 16 11 11 37 35 36
Book Value per Share		 ($1.39) ($1.93) ($2.37) ($1.98) ($2.10) ($2.18) ($16.44) ($17.78) ($6.11) ($4.37) ($3.90)
Tangible Book Value per Share		 ($1.39) ($1.93) ($2.37) ($1.98) ($2.10) ($2.18) ($16.44) ($17.78) ($6.11) ($4.37) ($3.90)
Total Capital		 58 44 29 29 19 9.41 15 1.02 20 14 -5.25
Total Debt		 99 101 102 103 104 103 106 109 109 110 100
Total Long-Term Debt		 99 101 102 103 104 103 100 97 92 85 78
Net Debt		 9.13 35 27 47 64 73 75 90 72 81 83
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -31 -20 -25 -19 -18 -15 -13 -15 -14 -13 -16
Debt-free Net Working Capital (DFNWC)		 59 45 49 37 22 15 18 3.08 23 16 1.35
Net Working Capital (NWC)		 59 45 49 37 22 15 12 -8.13 6.60 -9.24 -21
Net Nonoperating Expense (NNE)		 17 8.34 9.88 -3.81 2.94 3.51 0.18 8.09 21 5.35 5.53
Net Nonoperating Obligations (NNO)		 9.70 36 28 47 64 73 75 90 72 81 83
Total Depreciation and Amortization (D&A)		 0.46 0.39 0.12 0.17 0.18 0.30 0.43 0.47 0.52 0.54 0.56
Debt-free, Cash-free Net Working Capital to Revenue		 -2,466.26% -1,474.28% -1,406.89% -806.41% -797.54% -648.41% -711.34% -1,784.79% -1,848.14% -2,035.36% -2,328.68%
Debt-free Net Working Capital to Revenue		 4,776.97% 3,251.88% 2,815.26% 1,535.29% 976.93% 669.06% 963.23% 355.18% 3,114.63% 2,443.93% 197.79%
Net Working Capital to Revenue		 4,776.97% 3,251.88% 2,815.26% 1,535.29% 976.93% 669.06% 660.42% -936.98% 877.53% -1,439.41% -3,100.88%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.72) ($195.52) ($13.92) ($3.36) ($5.12) ($68.48) ($1.50) ($2.45) ($2.18) ($1.03) ($0.54)
Adjusted Weighted Average Basic Shares Outstanding		 29.27M 113.81K 1.93M 2.52M 2.65M 158.44K 4.83M 7.84M 14.20M 12.21M 23.57M
Adjusted Diluted Earnings per Share		 ($1.72) ($195.52) ($13.92) ($3.36) ($5.12) ($68.48) ($1.50) ($2.45) ($2.18) ($1.03) ($0.54)
Adjusted Weighted Average Diluted Shares Outstanding		 29.27M 113.81K 1.93M 2.52M 2.65M 158.44K 4.83M 7.84M 14.20M 12.21M 23.57M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($195.52) $0.00 $0.00 $0.00 ($68.48) $0.00 $0.00 $0.00 ($1.03) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 29.27M 1.91M 2.35M 2.55M 2.67M 342.88K 6.06M 14.56M 21.87M 27.07M 30.88M
Normalized Net Operating Profit after Tax (NOPAT)		 -31 -14 -17 -12 -9.62 -7.32 -7.07 -11 -9.82 -7.20 -7.16
Normalized NOPAT Margin		 -9,059.77% -3,699.76% -2,906.20% -1,042.39% -4,494.39% -2,000.74% -4,207.92% -9,247.00% -10,024.29% -2,811.48% -3,473.84%
Pre Tax Income Margin		 -14,805.28% -5,919.15% -4,603.26% -751.72% -6,378.50% -2,966.94% -4,317.86% -15,989.17% -31,541.84% -4,900.39% -6,160.68%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -14.85 -5.75 -6.69 -1.42 -2.76 -1.78 -0.89 -3.60 -6.12 -1.93 -2.07
NOPAT to Interest Expense		 -10.40 -4.05 -4.69 -3.27 -2.82 -1.82 -1.77 -2.63 -2.28 -1.64 -1.70
EBIT Less CapEx to Interest Expense		 -14.85 -5.75 -6.69 -1.42 -2.76 -1.78 -0.89 -3.60 -6.12 -1.93 -2.07
NOPAT Less CapEx to Interest Expense		 -10.40 -4.05 -4.69 -3.27 -2.82 -1.82 -1.77 -2.63 -2.28 -1.64 -1.70
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.35% -0.45% -0.12% -0.33% -0.52% -0.80% -2.90% -1.96% -2.45% -2.30% -1.28%

Financials Breakdown Chart

BioXcel Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, BioXcel Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

BioXcel Therapeutics' net income appears to be on an upward trend, with a most recent value of -$69.90 million in 2025, rising from -$4.54 million in 2017. The previous period was -$59.60 million in 2024. Find out what analysts predict for BioXcel Therapeutics in the coming months.

BioXcel Therapeutics' total operating income in 2025 was -$50.46 million, based on the following breakdown:
  • Total Gross Profit: $478 thousand
  • Total Operating Expenses: $50.94 million

Over the last 8 years, BioXcel Therapeutics' total revenue changed from $0.00 in 2017 to $642 thousand in 2025, a change of 64,200,000.0%.

BioXcel Therapeutics' total liabilities were at $140.38 million at the end of 2025, a 6.8% increase from 2024, and a 5,906.8% increase since 2017.

In the past 8 years, BioXcel Therapeutics' cash and equivalents has ranged from $887 thousand in 2017 to $232.97 million in 2021, and is currently $28.42 million as of their latest financial filing in 2025.

Over the last 8 years, BioXcel Therapeutics' book value per share changed from -0.10 in 2017 to -4.37 in 2025, a change of 4,204.8%.


Related Companies

Financial statements for NASDAQ:BTAI last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel